Mistral Pharma Inc. Announces Implementation of its Proposal
Monday, 29 September 2008 02:41 PM
The Corporation satisfied the conditions for implementation of the proposal filed by the Corporation on August 19, 2008 under the Bankruptcy and Insolvency Act (Canada) ("BIA") and the reorganization under Section 191 of the Canada Business Corporation Act included therein (the "Proposal"). The transactions contemplated under the Proposal have been completed. The Corporation obtained creditor approval of the Proposal on September 4, 2008 and a final order of the Quebec Superior Court of Justice (the "Court") under the BIA on September 15, 2008.
Pursuant to the Proposal, all affected creditors of the Corporation will receive a distribution under the Proposal in compromise and settlement of their affected claims. Pharmascience Inc. has funded the distributions that the Court-appointed trustee will provide to affected creditors and in return has received new common shares in the capital of the Corporation, becoming the Corporation's sole shareholder.
All common shares and other securities in the capital of the Corporation outstanding prior to the implementation of the Proposal have been automatically cancelled. All warrants, rights, options, agreements and instruments to purchase shares of the Corporation existing prior to the Proposal implementation are of no further force or effect.
The common shares of the Corporation will be de-listed from the TSX Venture Exchange at the close of business on September 30, 2008.
The Corporation will voluntarily surrender its reporting issuer status in the Province of British Columbia and has applied to cease to be a reporting issuer in the Provinces of Quebec, Ontario and Alberta.
SOURCE: Mistral Pharma inc.
Caroline McNicoll, Secretary, Mistral Pharma Inc., (514) 340-9800
